Protalix Biotherapeutics Inc logo

PLX - Protalix Biotherapeutics Inc Share Price

$5.55 0.3  4.7%

Last Trade - 6:15pm

Small Cap
Market Cap £175.1m
Enterprise Value £204.4m
Revenue £45.8m
Position in Universe 4369th / 6841
Unlock PLX Revenue
Relative Strength (%)
1m +5.05%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
4.36 9.20 21.1 34.2 54.7 62.9 60.5 78.4 +70.5%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, ProtalixBiotherapeutics Inc revenues increased 15% to $62.9M. Netloss decreased 64% to $6.5M. Revenues reflect License AndService increase of 20% to $46.7M, Product increase of 2%to $16.2M. Lower net loss reflects RESEARCH AND DEVELOPMENTEXPENSES - decrease of 16% to $37.2M (expense), General &admin expenses decrease of 5% to $9.1M (expense), FINANCIALINCOME increase of 8% to $438K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


PLX Revenue Unlock PLX Revenue

Net Income

PLX Net Income Unlock PLX Revenue

Normalised EPS

PLX Normalised EPS Unlock PLX Revenue

PE Ratio Range

PLX PE Ratio Range Unlock PLX Revenue

Dividend Yield Range

PLX Dividend Yield Range Unlock PLX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PLX EPS Forecasts Unlock PLX Revenue
Profile Summary

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated March 30, 2016
Public Since September 6, 2010
No. of Shareholders: n/a
No. of Employees: 207
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange NYSE MKT
Shares in Issue 45,382,831
Free Float (0.0%)
Eligible for
PLX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for PLX
Upcoming Events for PLX
Frequently Asked Questions for Protalix Biotherapeutics Inc
What is the Protalix Biotherapeutics Inc share price?

As of 6:15pm, shares in Protalix Biotherapeutics Inc are trading at $5.55, giving the company a market capitalisation of £175.1m. This share price information is delayed by 15 minutes.

How has the Protalix Biotherapeutics Inc share price performed this year?

Shares in Protalix Biotherapeutics Inc are currently trading at $5.55 and the price has moved by 0.116k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Protalix Biotherapeutics Inc price has moved by 44.69% over the past year.

What are the analyst and broker recommendations for Protalix Biotherapeutics Inc?

There are no analysts currently covering Protalix Biotherapeutics Inc.

When will Protalix Biotherapeutics Inc next release its financial results?

Protalix Biotherapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Protalix Biotherapeutics Inc dividend yield?

Protalix Biotherapeutics Inc does not currently pay a dividend.

Does Protalix Biotherapeutics Inc pay a dividend?

Protalix Biotherapeutics Inc does not currently pay a dividend.

When does Protalix Biotherapeutics Inc next pay dividends?

Protalix Biotherapeutics Inc does not currently pay a dividend.

How do I buy Protalix Biotherapeutics Inc shares?

To buy shares in Protalix Biotherapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Protalix Biotherapeutics Inc?

Shares in Protalix Biotherapeutics Inc are currently trading at $5.55, giving the company a market capitalisation of £175.1m.

Where are Protalix Biotherapeutics Inc shares listed? Where are Protalix Biotherapeutics Inc shares listed?

Here are the trading details for Protalix Biotherapeutics Inc:

Country of listing: United States
Exchange: ASQ
Ticker Symbol: PLX
What kind of share is Protalix Biotherapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Protalix Biotherapeutics Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Protalix Biotherapeutics Inc share price forecast 2021?

Shares in Protalix Biotherapeutics Inc are currently priced at $5.55. At that level they are trading at 0.145% discount to the analyst consensus target price of 0.00.

Analysts covering Protalix Biotherapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.015 for the next financial year.

How can I tell whether the Protalix Biotherapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Protalix Biotherapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 20.2%. At the current price of $5.55, shares in Protalix Biotherapeutics Inc are trading at 33.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Protalix Biotherapeutics Inc PE Ratio?

We were not able to find PE ratio data for Protalix Biotherapeutics Inc.

Who are the key directors of Protalix Biotherapeutics Inc?

Protalix Biotherapeutics Inc's management team is headed by:

Zeev Bronfeld - CHM
Amos Bar-Shalev - IND
Einat Almon - SVP
Aharon Schwartz - IND
Yaron Naos - SVP
David Granot - IND
Dror Bashan - PRE
Eyal Rubin - CFO
Pol Boudes - DRC
Gwen Melincoff - DRC
Yael Hayon - VRD
Who are the major shareholders of Protalix Biotherapeutics Inc?

Here are the top five shareholders of Protalix Biotherapeutics Inc based on the size of their shareholding:

Dexcel Pharma Technologies, Ltd. Corporation
Percentage owned: 10.04% (4.56m shares)
Angels Investments in Hi Tech, Ltd. Corporation
Percentage owned: 6.21% (2.82m shares)
Akirov (Alfred) Individual Investor
Percentage owned: 5.54% (2.51m shares)
Burrage Capital Management LLC Hedge Fund
Percentage owned: 5.44% (2.47m shares)
HIR Investments Ltd Corporation
Percentage owned: 4.84% (2.20m shares)
Similar to PLX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.